Efficacy News and Research

RSS
GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

GTC Biotherapeutics reports lower total net loss of $7.7M for first-quarter 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Capstone Therapeutics to continue to planned 12-month endpoints in AZX100 Phase 2a clinical trials

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Meda acquires European rights to new imiquimod formulation for AK from Graceway Pharmaceuticals

Researchers discover molecular mechanism behind smoking cessation effect

Researchers discover molecular mechanism behind smoking cessation effect

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Optivia Biotechnology launches OptiDDI Suite for assessing transporter-related DDIs

Oncos Therapeutics completes € 4 million investment from HealthCap

Oncos Therapeutics completes € 4 million investment from HealthCap

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

OXiGENE reports consolidated net loss of $11.0M for first-quarter 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

BSD, ProZyme partner to redefine biotherapeutic glycan analysis workflow

BSD, ProZyme partner to redefine biotherapeutic glycan analysis workflow

Gene variations may increase risk of developing schizophrenia: Study

Gene variations may increase risk of developing schizophrenia: Study

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

LifeWatch Services to unveil advanced AF TeleClinic service at HRS Annual Meeting

LifeWatch Services to unveil advanced AF TeleClinic service at HRS Annual Meeting

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

Sucampo presents phase 3 trial results of lubiprostone in non-cancer pain patients with OBD at DDW 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.